Christine L. Phillips, MD

Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Analysis of the Effect of Current Tisagenlecleucel (tisa-cel) Manufacturing in Pediatric and Young Adult Patients (pts) with ALL. Rouce, RH; Dolan, JG; Phillips, CL; Qayed, M; Pulsipher, MA; Vernau, LM; Galletta, TJ; Votaw, S; Caraballo, GL; Yang, H; Tesfaye, M; Lee, S; O'Sullivan, E; Grupp, SA. Transplantation and Cellular Therapy. 2025; 31:s219.

Impact of Graft Versus Host Disease Following Allogeneic Hematopoietic Cell Transplantation on Leukemia Free Survival in Hematologic Malignancies: A CIBMTR Analysis. Bauchat, A; Peterson, A; Ahn, KW; Mehta, PA; Phillips, CL; Schultz, KR; Sharma, A; Broglie, L; Qayed, M. Transplantation and Cellular Therapy. 2025; 31:s60-s61.

Impact of Current Manufacturing on Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Study of Tisagenlecleucel (tisa-cel)-Treated Pediatric and Young Adult Patients (pts) with ALL. Rouce, R; Dolan, JG; Phillips, CL; Qayed, M; Pulsipher, MA; Vernau, LM; Galletta, TJ; Votaw, S; Llaurador Caraballo, G; Yang, H; Tesfaye, M; Lee, S; O'Sullivan, E; Grupp, SA. Blood. 2024; 144:7724.

Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis. Rangarajan, H; Chellapandian, D; Atshan, R; Wooahn, K; Sharma, A; Schultz, KR; Mehta, PA; Phillips, CL; Broglie, L; Satwani, P. Blood. 2024; 144:2412.

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. LeBlanc, FR; Breese, EH; Burns, KC; Chang, EK; Jones, LQ M; Lee, L; Mizukawa, B; Norris, RE; O'Brien, MM; Phillips, CL; Perentesis, JP; Rubinstein, J; Pommert, L. British Journal of Haematology. 2024; 205:1055-1066.

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. Barsan, V; Li, Y; Prabhu, S; Baggott, C; Nguyen, K; Pacenta, H; Phillips, CL; Rossoff, J; Stefanski, H; Talano, J; Curran, KJ; Mackall, CL; Laetsch, TW; Schultz, LM. EClinicalMedicine. 2023; 65:102268.

Mediport use as an acceptable standard for CAR T cell infusion. Eylon, M; Prabhu, S; John, S; King, MJ M; Bhatt, D; Curran, KJ; Erickson, C; Karras, NA; Phillips, CL; Satwani, P; Fabrizio, VA; Baggott, C; Laetsch, TW; Schultz, LM. Frontiers in Immunology. 2023; 14:1239132.

Male pediatric, adolescent, and young adult reproductive survivorship. Burns, K; Phillips, C; Brannigan, R; Franklin, A; Howell, J; Schmidt, D; Sopfe, J; Appiah, LC; Anazodo, A. Pediatric Blood and Cancer. 2023; 70 Suppl 5:e28823.

Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. Phillips, CL; Krupski, C; Khoury, R; Dandoy, CE; Nelson, AS; Galletta, TJ; Faulhaber, A; Davies, SM; Rubinstein, JD. Frontiers in Hematology. 2023; 2:1151744.

Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Galletta, TJ; Rubinstein, JD; Krupski, C; Nelson, AS; Khoury, R; Dandoy, CE; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2023; 70:e30271.